Sandoz agreed to resolve lingering U.S. antitrust claims over alleged generic drug price-fixing through a pair of settlement agreements. The settlements cover claims brought by 43 U.S. states and territories, with Sandoz offering $400 million over seven years beginning in 2027 plus an additional $50 million to states that already settled related matters. A second settlement targets a putative class of indirect reseller plaintiffs, including retail pharmacies, clinics, hospitals, and other entities, with a $28.5 million offer. Sandoz said the agreements do not constitute an admission of wrongdoing and described the terms as consistent with ongoing efforts to close out class actions inherited after the Novartis spinout. If approved, Sandoz said the latest agreements would resolve remaining federal and state government claims in the matter, leaving only individual plaintiffs that opted out of class settlements. The company also emphasized the settlements will not affect its 2026 financial expectations or mid-term outlook.